FLT3 mutations can be classified into either internal tandem duplicates (ITD) (representing approximately 25% of AML patients) and point mutations in the tyrosine kinase domain (TKD) (approximately 5% of AML patients) (93). Here, FLT3 is linked to acute myeloid leukemia.